Beijing Inst. of Radiation Medicine TLR2 compound A-18

Beijing Inst. of Radiation Medicine TLR2 compound A-18: sourced facts only. name: "Therefore, our studies not only discovered A-18, a TLR2/1 small-molecule agonist, as a promising lead compound for the treatment of acute radiation syndrome (ARS) but also demonstrated that TLR2/1 small-molecule agonists can serve as a source of anti-radiation active compounds." [PMID:41930544]; target: "Therefore, our studies not only discovered A-18, a TLR2/1 small-molecule agonist, as a promising lead compound for the treatment of acute radiation syndrome (ARS) but also demonstrated that TLR2/1 small-molecule agonists can serve as a source of anti-radiation active compounds." [PMID:41930544]; developer: "School of Pharmacy, Henan University, Kaifeng, Henan 475004, PR China; Beijing Institute of Radiation Medicine, 27 Taiping Road, Beijing 100850, PR China." [PMID:41930544]; modality: "Therefore, our studies not only discovered A-18, a TLR2/1 small-molecule agonist, as a promising lead compound for the treatment of acute radiation syndrome (ARS) but also demonstrated that TLR2/1 small-molecule agonists can serve as a source of anti-radiation active compounds." [PMID:41930544]; stage: "In mice irradiated with 8.5 Gy 60Co γ-ray total body irradiation, prophylactic administration of A-18 achieved a 30-day survival rate of 100%, while A-18 administration post-irradiation still increased the survival rate to 40%." [PMID:41930544]